Patient characteristics.
| Characteristics | GBC (n=36) | CHOL (n=62) | All (n=98) |
| Age at initial diagnosis (years) | |||
| Median (range) | 63.3 (42–80) | 58.3 (35–74) | 60.1 (35–80) |
| Gender | |||
| Male | 17 (47.2%) | 27 (43.5%) | 44 (44.9%) |
| Female | 19 (52.8%) | 35 (56.5%) | 54 (55.1%) |
| ECOG PS at initial diagnosis | |||
| 0–1 | 27 (75.0%) | 43 (69.4%) | 70 (71.4%) |
| 2–3 | 4 (11.1%) | 12 (19.4%) | 16 (16.4%) |
| Unknown | 5 (13.9%) | 7 (11.2%) | 12 (12.2%) |
| Histology grade | |||
| 2 | 7 (19.4%) | 13 (21.0%) | 20 (20.4%) |
| 3 | 17 (47.3%) | 24 (38.7%) | 41 (41.8%) |
| Unknown | 12 (33.3%) | 25 (40.3%) | 37 (37.8%) |
| Treatment of first-line immunotherapy* | |||
| Yes | 12 (33.3%) | 22 (35.5%) | 34 (34.7%) |
| No | 24 (66.7%) | 40 (64.5%) | 64 (65.3%) |
*Patients were treated by camrelizumab plus gemcitabine and oxaliplatin from the NCT03486678 trial.
CHOL, cholangiocarcinoma; GBC, gallbladder cancer; ECOG PS, Eastern Cooperative Oncology Group Performance Status.